The unwarranted effects of medications used in psychiatry can adversely affect a treatment plan. This book is critical in helping psychiatrists and mental health professionals assess the adverse effects of drugs such as antidepressants, mood stabilizers, hypnosedatives, and antipsychotic drugs.
The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler's Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.
This volume is critical for any health professional involved in the administration of psychiatric mediations.
- Surpasses the Physician's Desk Reference © by including clinical case studies and independent expert analysis
- Complete index of drug names
- Most complete cross referencing of drug-drug interactions available
- Extensive references to primary and secondary literature
- Also includes information on adverse effects in pregnancy
The book is divided into six sections:
- Antidepressants - A general introduction to their adverse effects, followed by monographs on individual drugs and groups of drugs (including lithium)
- Neuroleptic drugs - A general introduction to their adverse effects, followed by monographs on individual drugs
- Hypnosedatives - A general introduction to their adverse effects, followed by monographs on individual drugs
- Drugs of abuse
- Drugs used to treat Alzheimer's disease
- Psychological and psychiatric adverse effects of non-psychoactive drugs
Selective Serotonin Re-uptake Inhibitors (SSRIS)
Monoamine Oxidase Inhibitors
Drugs of Abuse
Methylenedioxymetamfetamine (MDMA, Ecstasy)
Drugs Used in Alzheimer's Disease 629
Psychological and Psychiatric Adverse Effects of Non-psychoactive Drugs
Index of Drug Names
Dr Jeffrey K. Aronson is a consultant clinical pharmacologist and physician in the Department of Primary Health Care in the University of Oxford and a consultant physician in the Oxford Radcliffe Hospitals Trust. He has been associated with the Meyler series since 1977 and has published many research papers on adverse drug reactions. He is President of the British Pharmacological Society and serves on many committees concerned with drug therapy, including the Technology Appraisal Committee of the UK's National Institute for Health and Clinical Excellence (NICE) and the Joint Formulary Committees of the British National Formulary and the British National Formulary for Children.